Severe Inherited Inborn Errors of Metabolism

Tay-Sachs Disease

Inherited GM2 Gangliosidosis Lysosomal Storage Disorder

Primary risk age: Infants (onset of symptoms typically between 3 and 6 months of age)

Urgency: Severe
Typical age: Infants (onset of symptoms typically between 3 and 6 months of age)
Body system: Endocrine & Metabolic

Typical course: This is a progressive, fatal genetic neurodegenerative disorder; management is supportive and palliative throughout the child's life.

Reviewed against AAP · CDC · WHO · NHS guidance Last reviewed 2026-06-13

1. Summary & Pathophysiology

Inherited GM2 Gangliosidosis Lysosomal Storage Disorder

Pathophysiology (Development Path)

Deficiency of hexosaminidase A prevents the degradation of GM2 gangliosides in cell lysosomes. GM2 gangliosides accumulate to toxic levels in neuronal lysosomes, causing progressive cell swelling, myelin breakdown, and widespread neurodegeneration.

Primary Causes & Etiology

Autosomal recessive mutations in the HEXA gene on chromosome 15, causing a deficiency of the enzyme beta-hexosaminidase A.

2. Symptom Continuum

Early Onset Signs
Mild motor delays, loss of head control, and an exaggerated startle response to loud noises (hyperacusis) between 3 and 6 months.
Progressive Phase
Loss of ability to sit, crawl, roll over, or smile. Marked muscle weakness, loss of focus, and a diagnostic macular "cherry-red spot" on retinal exam.
Severe Indicators
Recurrent generalized seizures, blindness, deafness, progressive spasticity, dysphagia (swallowing failure), decerebrate posturing, and complete vegetative state.

3. Clinical Verification

Measurement of beta-hexosaminidase A activity in white blood cells or serum (showing absent or near-absent activity). Confirmed by HEXA gene sequencing.

4. Care & Elements Plan

Primary Care Treatment Plan

Supportive, palliative, and symptomatic care. No curative or disease-modifying therapies currently exist. Focus on seizure control, chest physical therapy to prevent pneumonia, and nutritional support (G-tube placement).

Home Support Elements

Provide gentle comfort care (positioning, suctioning). Administer medications to control seizures. Maintain range-of-motion exercises to prevent joint contractures. Seek emotional support for the family.

Generic Active Ingredients (No Brands)

Levetiracetam or Phenobarbital (generic antiepileptic active ingredients to manage seizures)
Glycopyrrolate (to dry secretions and prevent drooling/aspiration).

Lists active elements only. Never administer self-designed therapies.

5. Doctor Critical Lines

Critical Thresholds: When to See a Doctor

Consult a pediatrician if a previously normal 3-6 month old infant starts losing motor milestones, fails to hold their head up, or shows an exaggerated startle response to noise.

6. Vaccine & Prevention

Routine Prophylaxis (Prevention)

Pre-conception genetic screening for carrier status (especially in high-risk populations such as Ashkenazi Jewish cohorts); prenatal diagnosis (amniocentesis/CVS).

Immunization Context

Supportive immunizations are recommended, but do not alter the course of this lysosomal storage disorder.

7. Timelines & Outlook

Active Timeline

This is a progressive, fatal genetic neurodegenerative disorder; management is supportive and palliative throughout the child's life.

Expected Prognosis

Fatal. The condition is progressive and leads to death, typically by age 2 to 5, usually due to aspiration pneumonia.

Potential Untreated Complications

Generalized seizures, aspiration pneumonia, dysphagia, decerebrate rigidity, and premature death.

Severe

Phenylketonuria (PKU)

Inborn Error of Amino Acid Metabolism

Neonates (Screened at birth; symptoms develop over the first year if untreated)

Emergency

Classic Galactosemia

Inborn Error of Carbohydrate Metabolism

Neonates (Symptoms present within days of initiating milk feeding)